<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Heidi Lyng | Theragnostic Imaging</title>
    <link>https://www.theragnostics.no/en/author/heidi-lyng/</link>
      <atom:link href="https://www.theragnostics.no/en/author/heidi-lyng/index.xml" rel="self" type="application/rss+xml" />
    <description>Heidi Lyng</description>
    <generator>Hugo Blox Builder (https://hugoblox.com)</generator><language>en-us</language><lastBuildDate>Tue, 01 Nov 2022 00:00:00 +0000</lastBuildDate>
    <image>
      <url>https://www.theragnostics.no/media/icon_hu14557955862192370321.png</url>
      <title>Heidi Lyng</title>
      <link>https://www.theragnostics.no/en/author/heidi-lyng/</link>
    </image>
    
    <item>
      <title>Risk of recurrence after chemoradiotherapy identified by multimodal MRI and 18F-FDG-PET/CT in locally advanced cervical cancer</title>
      <link>https://www.theragnostics.no/en/publications/skipar-2022-risk/</link>
      <pubDate>Tue, 01 Nov 2022 00:00:00 +0000</pubDate>
      <guid>https://www.theragnostics.no/en/publications/skipar-2022-risk/</guid>
      <description>&lt;hr&gt;
&lt;p&gt;MRI, applying dynamic contrast-enhanced (DCE) and diffusion-weighted (DW) sequences, and 18F-fluorodeoxyglucose (18F-FDG) PET/CT provide information about tumor aggressiveness that is unexploited in treatment of locally advanced cervical cancer (LACC). We investigated the potential of a multimodal combination of imaging parameters for classifying patients according to their risk of recurrence. Eighty-two LACC patients with diagnostic MRI and FDG-PET/CT, treated with chemoradiotherapy, were collected. Thirty-eight patients with MRI only were included for validation of MRI results. Endpoints were survival (disease-free, cancer-specific, overall) and tumor control (local, locoregional, distant). K&lt;sup&gt;trans&lt;/sup&gt;, reflecting vascular function, apparent diffusion coefficient (ADC), reflecting cellularity, and standardized uptake value (SUV), reflecting glucose uptake, were extracted from DCE-MR, DW-MR and FDG-PET images, respectively. By applying an oxygen consumption and supply-based method, ADC and K&lt;sup&gt;trans&lt;/sup&gt; parametric maps were voxel-wise combined into hypoxia images that were used to determine hypoxic fraction (HF). HF showed a stronger association with outcome than the single modality parameters. This association was confirmed in the validation cohort. Low HF identified low-risk patients with 95% precision. Based on the 50th SUV-percentile (SUV&lt;sub&gt;50&lt;/sub&gt;), patients with high HF were divided into an intermediate- and high-risk group with high and low SUV&lt;sub&gt;50&lt;/sub&gt;, respectively. This defined a multimodality biomarker, HF/SUV&lt;sub&gt;50&lt;/sub&gt;. HF/SUV&lt;sub&gt;50&lt;/sub&gt; increased the precision of detecting high-risk patients from 41% (HF alone) to 57% and showed prognostic significance in multivariable analysis for all endpoints. Multimodal combination of MR- and FDG-PET/CT-images improves classification of LACC patients compared to single modality images and clinical factors.&lt;/p&gt;
</description>
    </item>
    
    <item>
      <title>Low dose-rate irradiation with [3H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model</title>
      <link>https://www.theragnostics.no/en/publications/mikalsen-2018-low/</link>
      <pubDate>Sat, 01 Sep 2018 00:00:00 +0000</pubDate>
      <guid>https://www.theragnostics.no/en/publications/mikalsen-2018-low/</guid>
      <description>&lt;hr&gt;
&lt;p&gt;Earlier in vitro studies show that irradiation with an ultra-low dose-rate of 15 mGy/h delivered with [&lt;sup&gt;3&lt;/sup&gt;H]-valine leads to loss of clonogenicity in hypoxic T-47D cells. Here, the aim was to determine if [&lt;sup&gt;3&lt;/sup&gt;H]-valine could be used to deliver low dose-rate irradiation in a colorectal cancer model. Clonogenicity was measured in cultured cancer cell line HT29 irradiated with 15 mGy/h combined with intermittent hypoxia. Mice with HT29 xenografts were irradiated by repeated injections of [&lt;sup&gt;3&lt;/sup&gt;H]-valine intravenously. The activity in the tumor tissue was measured by scintillation counting and tumor growth, hypoxic fraction and tritium distribution within tumors were assessed by pimonidazole staining and autoradiography. Ultra-low dose-rate irradiation decreased clonogenicity in hypoxic colorectal cancer cells. In vivo, the tumor growth, hypoxic fraction and weight of the mice were similar between the treated and untreated group. Autoradiography showed no [&lt;sup&gt;3&lt;/sup&gt;H]-valine uptake in hypoxic tumor regions in contrast to aerobic tissue. Continuous low-dose-rate irradiation was well tolerated by aerobic tissue. This indicates a potential use of low dose-rate irradiation to target hypoxic tumor cells in combination with high dose-rate irradiation to eradicate the well oxygenated tumor regions. However, [&lt;sup&gt;3&lt;/sup&gt;H]-valine is not the appropriate method to deliver ultra-low dose-rate irradiation in vivo.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
